Pharma Q1 Growth to be Driven by Domestic Formulations, Chronic Therapies, and Biosimilars

Pharma Q1 growth to be driven by domestic formulations, chronic therapies, and biosimilars, while US generics remain a drag on revenue.

Key Growth Drivers in Q1

Sun Pharmaceutical Industries is expected to report double-digit revenue growth, driven by strong performance in India and other emerging markets, while the US business may grow in mid-single digit. The specialty portfolio led by Leqselvi and Unloxcyt is expected to remain a key growth driver.

Aurobindo Pharma is likely to post revenue growth of around 15% year-on-year, supported by biosimilars, injectables, and strong European market performance. While the US business may remain subdued due to lower gRevlimid sales, healthy growth in antiretroviral (ARV) businesses, Europe, and RoW markets could provide support.

Focus Areas for Aurobindo Pharma

Key monitorables include the Lannett integration, offtake from the Pen-G facility, and resolution of USFDA observations at Eugia III plant.

Market Impact and Details

• Dr. Reddy’s Laboratories is expected to report a weak quarter, with revenue decline in the mid-single digits due to the absence of meaningful gRevlimid sales weighing on the US business.
• Lupin is expected to be among the stronger performers, aided by resilient US sales supported by delayed competition for g-Tolvaptan, and continued traction in Mirabegron.
• Cipla is expected to report a muted quarter as a sharp decline in US sales offsets healthy domestic growth.

Key Takeaways

• Domestic formulations and chronic therapies are expected to drive growth in Q1.
• Biosimilars and specialty products are expected to remain key growth drivers.
• US generics remain a drag on revenue, with some companies expected to report weak quarters.

FAQs

What are the key growth drivers in Q1?

Domestic formulations, chronic therapies, and biosimilars are expected to drive growth in Q1.

Which companies are expected to report strong growth in Q1?

Sun Pharmaceutical Industries, Aurobindo Pharma, Lupin, and Torrent Pharmaceuticals are expected to report strong growth in Q1.

What are the key monitorables for Aurobindo Pharma?

The key monitorables for Aurobindo Pharma include the Lannett integration, offtake from the Pen-G facility, and resolution of USFDA observations at Eugia III plant.

Conclusion

The Q1 results of pharmaceutical companies are expected to be driven by domestic formulations, chronic therapies, and biosimilars, while US generics remain a drag on revenue. Companies such as Sun Pharmaceutical Industries, Aurobindo Pharma, Lupin, and Torrent Pharmaceuticals are expected to report strong growth in Q1. Investors should keep an eye on the key monitorables for these companies, including the Lannett integration, offtake from the Pen-G facility, and resolution of USFDA observations at Eugia III plant.